Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Superinvestors holding ALVO, Q2 2026
1 superinvestor reports holding Alvotech on Form 13F, worth $361.6K in total. Weight is Alvotech's share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Oaktree CapitalHoward Marks | <0.1% | 97,982 | $361.6K | Reduced−59.2% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ALVO each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−59.2%)
Q1 2026
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−55.0%)
Q4 2025
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−65.9%)
Q2 2025
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−16.3%)
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−3.0%)
Q4 2024
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−23.9%)
Q2 2024
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−12.7%)
Q1 2024
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−46.8%)
Q4 2023
1 superinvestor holding at quarter end
- Added
- Oaktree Capital (+8.1%)
Q3 2023
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−25.4%)
Q2 2023
1 superinvestor holding at quarter end
- Reduced
- Oaktree Capital (−12.9%)
Q1 2023
1 superinvestor holding at quarter end
- Added
- Oaktree Capital (+22.5%)
Q2 2022
1 superinvestor holding at quarter end